Peregrine Pharmaceuticals (PPHM) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts PPHM Hot Sheet
Join SI Premium – FREE
Peregrine Pharmaceuticals (NASDAQ: PPHM) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $4.25 million versus the consensus estimate of $3.57 million.
For earnings history and earnings-related data on Peregrine Pharmaceuticals (PPHM) click here.
For earnings history and earnings-related data on Peregrine Pharmaceuticals (PPHM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX (SPCX) PT Raised to $230 at Goldman Sachs ahead of earnings release
- Goldman Sachs Downgrades Beiersdorf AG (BEI:GR) (BDRFY) to Sell
- Allegion acquires specialty door maker Overly Door Company
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
